Joshua Crossney: The Entrepreneur of Medicinal Cannabis in the United States.

Joshua Crossney: The Entrepreneur of Medicinal Cannabis in the United States.

Joshua has been the founder and pioneer in the United States of a major event on “Cannabis Science”, which he has called the “Cannabis Science Conference” which started in 2016 with 750 attendees and 75 stands of sponsors and exhibitors and it was made at The Red Lion Hotel. For the year 2017 they moved to the Downtown Portland Convention Center and achieved 2,000 attendees and 120 stands of sponsors and exhibitors. For this year 2018 continue at the Portland Dowtown Convention Center with an expectation to reach 2,500 attendees and 150 stands of sponsors and exhibitors, for all this is considered the world’s largest cannabis science conference and exhibition and Joshua Crossney is known today in the world as the synonym of ‘cannabis science’.

 

Joshua Crossney has created the JCanna Foundation, a 501 (c) 3 nonprofit organization comprised of affiliates that include cannabis industry experts, scientists, physicians, legislators and interested entrepreneurs who work together to promote the advancement of science of cannabis, analytical tests and personalized medicine (precision). Our affiliates work to share ideas and advanced solutions to improve the technologies of the medical cannabis analytical tests.

 

Joshua leads in the United States the use of medical cannabis analytical tests. Medicinal Cannabis offers an opportunity to heal people, and the last thing we want is for Medical Cannabis to make people sick, for not applying very high and complete testing standards that include, analysis of dangerous pesticides, heavy metals, residual solvents , microorganisms, aflatoxins, including analysis of dispensing materials and final product tests. This becomes much more relevant when dealing with young children who demand Medicinal Cannabis for epilepsy processes, because a contaminated Medicinal Cannabis offers more risks for them.

 

There are a series of phrases that Joshua has mentioned in his lectures and articles, I have selected some of them:

 

“What we know about Medicinal Cannabis is a drop and what we do not know about Medicinal Cannabis is an ocean.”

 

“There are many doctors who are not currently learning about Medicinal Cannabis in their medical training.”

 

“My passion is to help with medicinal cannabis to many patients in the world, especially pediatric patients.”

 

“I am excited to learn as much as I can about Medicinal Cannabis and to do my best to facilitate the education of others.”

 

“Every day I work to close the gap between analytical science and the Medicinal Cannabis industry, to help improve the quality of medical cannabis products used by patients.”

 

Fuentes:

https://www.medicaljane.com/2016/06/14/the-cannabis-contamination-conundrum/

https://theanalyticalscientist.com/fileadmin/tas/pdf-versions/0916_Cannabis_Supplement.pdf

Dr. Sue Sisley: “Veteran of Medicinal Cannabis Research in the World”

It is a pride as a Colombian to present Dr. Sue Sisley who will be in Colombia on April 20 and 21 to be a keynote speaker at the International Cannaciencia Symposium on Medicinal Cannabis.

 

It is a privilege for us to learn from Dr. Sue, whom I have called the “WARRIOR of Medicinal Cannabis Research in the World,” she is conducting a clinical trial on the effectiveness of Medicinal Cannabis in PTSD in war veterans from United States after being stonewalled by the US government for nearly 8 years.

Dr. Sue Sisley MD, has no problem talking about how Big Pharma blocks research in whole plant Medicinal Cannabis, as well as entrepreneurs in private prisons in the United States striving to suppress efficacy research.

 

Discusses the DEA’s monopoly on the supply of Medicinal Cannabis for research studies, delays in supply and when it is supplied may not be the phenotypes they requested, or of inferior quality, resulting in delays in research and sabotage results about the effectiveness that the study tries to demonstrate.

 

Dr. Sue is a self-proclaimed “lifelong Republican” and has introduced legislation against smoking in the workplace, so at the beginning she was not a typical champion of Medicinal Cannabis, but considered herself a skeptic and still does.

 

The way Dr. Sisley finally comes into contact with Medicinal Cannabis was after a decade of listening to her patients telling her how cannabis has changed their lives. She had received a large amount of anecdotal evidence that had prompted her to conduct the 1st controlled clinical trial of the effectiveness of medical cannabis on PTSD in United States war veterans.

 

Daniela Vergara: The precursor of Cannabis Genomics in the world present in Cannaciencia.

Daniela Vergara: The precursor of Cannabis Genomics in the world present in Cannaciencia.

Dr. Daniela Vergara is an evolutionary biologist researching Cannabis genomics at the University of Colorado Boulder. In addition to her multiple publications in Cannabis, she founded and directs a non-profit organization, the Agricultural Genomics Foundation (AGF; agriculturalgenomics.org).  AGF’s aim is to make Cannabis science available to a broad public.

 

Dr. Vergara’s latest scientific publications include the comparison of the federal Cannabis to that produced by the private market, showing that the government’s Cannabis lacked potency and variation. These results were featured in news platforms such as The Atlantic, Science and FiveThirtyEight. Some of her other scientific publications are a compilation on the existing genomic toolsavailable for Cannabis research, and the maternally inherited genomes (chloroplast and mitochondria). Vergara has authored these publications advised by Dr. Nolan Kane whose group at CU Boulder she joined in 2013. These publications are a product of collaborations between graduate and undergraduate students, and scientists from the Cannabis Industry.

 

Through AGF, Vergara educates the public about science, Cannabis, evolutionary biology, and genomics. AGF also supports the Cannabis Genomic Research Initiative (CGRI; CannabisGenomics.org), group that Drs. Vergara and Kane founded to explore the Cannabis genome.

 

Currently, Dr. Vergara is exploring the genes related to the production of CBD and THC, and is associating this important physical trait to the genome.

 

Most of Vergara’s research has been funded by private individuals who believe in her cause with donations to AGF that holds a 501(C)3 status.

 

Dr. Vergara will participate in Cannaciencia with the lecture titled: “5 facts about Cannabis Genomics” addressing the results from her research conducted in the Kane lab at the Ebio department in the University of Colorado in Boulder. Particularly, she will discuss five facts that her research has established: the genomic and phenotypic variation inCannabis varieties, the misnaming of these cultivars by the industry, the genes involved in cannabinoid production, and the phenotypic variation from the federally produced Cannabis. These projects are the first step to relate the plants’ genotype to their phenotype, which is crucial for breeding purposes, to understand the origins of this controversial plant, and to unravel the relationship between the cultivars

 

An approach to Dr. Uma Dhanabalan: Principal Speaker of Cannaciencia

An approach to Dr. Uma Dhanabalan: Principal Speaker of Cannaciencia


Dr. UMA, is a very special human being, the American Chronicle has called her the “Doctor of Cannabis”, but I propose to call her and recognize her as the “Heart Doctor”.

 

Yes, because it is from the heart that she educates, embraces and empowers her patients using her “Total Health Care THC ” model. The use of medicinal Cannabis as an alternative and/or adjunct to improve their quality of life in patients with multiple ailments withchronic and degerative conditions. Dr Uma’s in their treatments.

 

She wants all doctors, health care providers and people to know the facts about cannabis and the endocannabinoid system. Dr Uma states “cannabis is not for everyone yet it should be a first-line option and not the last resort .“ Dr Uma’s for h er dedication to educating people her patients and her medical colleagues was recognized at The Cannabis Business Awards 2017 as the most valuable professional (MVP) in the category “Achievements in Educational achiement Award of Medicinal Cannabis” in the United States.

 

Before becoming a certified family physician in the use of Medicinal Cannabis, she experienced a painful episode in her life, her mother died of idiopathic pulmonary fibrosis, without which she could have done much to help her, today she knows that Medicinal Cannabis It has been of great help for this type of ailment, that is why from its great heart the purpose is to educate many doctors who can help many patients in this type of ailment.

 

Her heart also harbors a great love for her country of origin; India, and works hard so that very soon the use of Medicinal Cannabis is legalized, and although it seems paradoxical it was from India where Cannabis migrated to the American continent, and many countries like Colombia many patients and people start to benefit for Medicinal Cannabis.

 

For Cannaciencia and for Colombians it is a privilege to have this great human being, who wishes from the bottom of her heart that the Cannabis Medicinal industry is a success in Colombia and she comes to do her bit to make it come true very soon.

Paul Mavor tells us how Australia dabbled in Medicinal Cannabis

Paul Mavor tells us how Australia dabbled in Medicinal Cannabis

 

From Cannaciencia, we welcome Paul Mavor and his wife Sharlene Mavor, they have been the pioneers of the Medicinal Cannabis industry in Australia.

 

We have conducted an interview, which we would like to share, as an introduction to what your participation as lecturers of the Cannaciencia Symposium will be on the next 20 and 21 April 2018 in the city of Bogotá.

 

RM: Ricardo Martínez Rivadeneira  – PM: Paul Mavor
RM: What do you consider the critical success factors of the medicinal cannabis industry in Australia?
PM: We are a very new industry compared to other countries who have been doing this for a while. It is important to look at other countries such as the US, Canada and Israel and see what has worked and what has not. Our government has followed very closely and tried to implement a good framework for success. As a result there is lots of interest in research projects by scientists and support from the government. This will hopefully benefit us in the long run.

 

RM: What have been the main achievements of the Australian medicinal cannabis industry to date?
PM: We became legal in November 2016
First imported (Canadian) products arrived May 2017
A number of growing/manufacture/research licenses have been issued
Our government has also just allowed Australian companies to export our products once they come online

 

RM: At this time, what are the main future challenges for the medicinal cannabis industry in Australia?
PM: The big challenge at this stage is patient access. The bar has been set very high for doctors to write prescriptions and involves a lot of paperwork. Federally we have a very good system. Unfortunately our local state health departments who were in charge of banning cannabis have implemented a very difficult system. This will hopefully change over time.

 

RM: What recommendations would you give to the nascent medicinal cannabis industry in Colombia?
PM: We are still very your ourselves so are looking to other countries and what has worked well. Australia has adopted a very strict medical system. I think this is important moving forward as whilst it is slow to begin with rigorous testing and research in the long run it will make for a better more sought after product. In most all cases in the US and Canada it has been legalised as a very medical industry this has worked well and then a number of years down the track the authorities have relaxed the laws to make patient access easier.

 

RM: What has it meant for you to be the pioneers of the medicinal cannabis industry in Australia?
PM: This is a really progressive industry to be involved in and things are moving very fast. We are really excited to be able to travel within our country and overseas (especially Colombia!) and attend conferences and talk about this. Most of the people involved in this industry tend to be very forward thinking and progressive. Things change on a daily basis so we constantly have to keep up to date.

 

RM: What are you recommendations about analytical testing for the emerging industry in Colombia?

PM: We learnt very early on that testing of cannabis for potency and purity is key. There were a lot of disappointed people who were just hoping to grow their cannabis and sell it. This might be okay when you are growing it for yourself but when you are supplying a product to others you need to fulfil some key obligations and make sure the product is what is stated. The cannabis plant is generally very safe but the plant itself is a bio-accumulator and absorbs everything in the soil. When the flower is extracted and concentrated this may also concentrate any contaminants such as pesticides or heavy metals. There have been issues in the US and Canada where sample testing has shown a few shortcuts were taken in the production process and we have learnt from that. Testing is important for consumer confidence. It would be no different if we were making any product sold to the pubic even bottled water. If there were any problems it could affect our entire industry.

 

We thank Paul Mavor for this interview, we are close to listening to his conference at the Cannaciencia Symposium, we invite you to register and not miss the opportunity to learn from Paul Mavor.

The social drama of post-traumatic Stress in the Armed Forces

The social drama of post-traumatic Stress in the Armed Forces

A country like Colombia with more than 50 years of conflict and wars with mafias, drug traffickers, paramilitaries, guerrillas with confrontations, massacres, terrorist attacks that have left more than 8 million dead (almost 20% of the population). In this country, one of the most violent countries in the world, there is ample evidence to believe that post-traumatic stress exists not only in the military and police but also in the civilian population that has been exposed to these traumatic acts of cruelty.

 

The families of soldiers fighters in the war against the FARC suffering from the Stress-Traumatic of their children, parents and brothers, who lost in the first moment they returned from the war, with a irritable, evil and disconnected from the family behavior.
.

It is painful to see this situation of people, who by giving the rest of Colombians, the security mentioned in the constitution, have to pay such a high price: in some cases their lives in combat or their lives on returning from combat as a result of the medications that they consume to attenuate the symptoms of post-traumatic stress (mostly opioids) or suicidal tendencies generated by this type of stress.

 

This is a drama lived by thousands of relatives of the military and police, who agreed that they will provide a service to the country, a very expensive and painful service for all.

 

In other countries with more developed economies such as Canada, the United States and Israel, they are taking steps to recover these soldiers for their families and their country. In Colombia there are still no studies, and there has been very little interest in this topic.

 

Colombia is a privileged country, in August of 2016 the Colombian Congress approved a new law that regulates the medicinal use of cannabis, let’s try to work together to put our contribution and power among all to solve the Post Traumatic Stress of both the military and police, as of displaced families and victims of violence.

 

Let’s all work together to hear phrases from children like: “I recovered my dad” after years of [him] being disconnected, irritable and evil “, and wives also saying: “I recovered my husband.” This is a happiness that has no price and for which we want to contribute in this Cannaciencia symposium.

 

Through Dr. Sue Sisley, the only doctor in the world who conducts a clinical study on the benefits of medical cannabis in US veterans with post-traumatic stress, approved by the FDA.

Post-traumatic Stress in the armed forces

Post-traumatic Stress in the armed forces

Anyone, regardless of their age or circumstance, who has experienced a traumatic event may be susceptible to PTSD (Post Traumatic Stress Disorder – the inability of some people to extinguish traumatic memories).

 

After a traumatic event, patients with PTSD are likely to feel feelings and thoughts related to the trauma, experience nightmares, memories, emotional distress, and hypervigilance among a host of other symptoms.

 

Post-traumatic stress is mainly due to fear learned. When you have more fear learned, that will induce a state of hypervigilance and that can also cause nightmares and terrors at night. This learned fear makes it difficult to modulate feelings and reactions, especially with respect to situations that trigger memory or trauma experience.

 

The extinction of memory occurs naturally, organically in the average population. However, some people who have experienced a trauma or traumatic event have an impairment to their natural capacity for memory extinction.

 

According to the US National Center for PTSD UU., More than 8% of the US population. UU suffers from post-traumatic stress disorder, 26% of which are men and women of military service. In Israel, approximately 9% of citizens have been diagnosed with post-traumatic stress disorder, a country where military service and reserve duty is mandatory, and who have generally lived in permanent war, post-traumatic stress disorder It is frequent. Canada has some of the highest rates of PTSD, with an estimated 9.4 percent of the population experiencing some form of the disease

 

Conventional treatments against PTSD include powerful sedatives, antidepressants, anti-anxiety drugs and, in extreme cases, antipsychotics. Most of these medications are based on opioids, which can cause a variety of devastating side effects (restlessness, anxiety) and long-term problems (tachycardia, addiction, and suicidal tendencies). This has led to an epidemic of opioids, which has led to a considerable increase in deaths.

 

This has become in these countries a problem that has demanded attention and answers aimed at solving it in a different way.

 

Medical cannabis has been shown to support the extinction capabilities of the body’s endogenous memory, reducing the ability of traumatic memories to trigger the symptoms of PTSD.

 

Cannabis is a much better and safer and more effective alternative. Because of its antisuppressive, anti-stress and anti-depressant properties, it also allows reducing the deficiency of Anandamide, common in patients with PTSD.

 

The most advanced countries in the application of medical cannabis in PTSD are: United States, where the Dr. Sue Sisley is internationally recognized expert, in Canada is Dr. Mike Hart who along with movements such as Marijuana for Trauma (https://mftgroup.ca/) have become standard bearers of the TEP, in Israel are Dr. Irit Akirav of the University of Haifa, and Dr. Yasmin Hurd, and movements such as: Lochamim Lchaim – Fighting for Life (http://lohamim.org.il/).

 

Dr. Sue Sisley is the Principal Investigator of the only FDA-approved randomized controlled trial in the world that examines the safety and efficacy of medical cannabis in combat veterans with treatment-resistant post-traumatic stress disorder. The study is the largest awarded by the Department of Public Health and Environment CDPHE Colorado (US $ 2.1M)

 

Veterans represent 20% of national suicide rate, this translates into 22 veterans who commit suicide every day, in three years the number of veterans who have committed suicide totals 24,000. These veterans correspond to those resistant to the treatment of PTSD.

 

Patients with PTSD suffer a comorbidity rate, which means that they experience more than one condition at a time. 79% of women and 88% of men diagnosed with PTSD also suffer from depression, substance abuse and anxiety disorders. Given the growing evidence that cannabis is a treatment for depression, anxiety and substance abuse, the potential benefit of cannabis treatment for comorbidity is very promising. This, combined with a growing body of evidence that the endocannabinoid system has a role in reducing fear and anxiety, suggests that cannabinoids can also have positive effects in reducing suicidal thoughts and behaviors.

 

There is great potential for medical cannabis to become a multi-therapy, rather than having to take as many different medications for all the symptoms and parallel conditions as monotherapy.

The social drama of epilepsy

The social drama of epilepsy

A large number of families, mostly mothers who are heads of households with limited resources, illegally obtain cannabis and prepare it in an artisanal and anti-hygienic way in their gas stoves, using the pots where they cook their food, assuming all possible types of risks, in order to alleviate the suffering and convulsions of their children with epilepsy.

 

They do this in the face of their impotence, that the medicines they give them in the health service, fail to offer a real and evident improvement in their children, who continue to convulse and suffer this terrible disease.

 

Someone told them about the benefits and effectiveness of medicinal cannabis oil extract (CBD – the good part of Cannabis) and without thinking much have begun to prepare it to give to their children. The good results have generated several movements of mothers who, using social networks, have begun to tell the testimonies of their children.

 

This is a public health issue, which is repeating itself in all countries of the world, there are countries like Chile, where what is happening is that medical cannabis is being imported from Canadian laboratories and sold at such high prices that families of scarce resources can not buy it and are opting to grow cannabis illegally to prepare medicinal cannabis oil also illegally, at a more reasonable price for them.

 

Colombia is a privileged country, in August of 2016 the Colombian Congress approved a new law that regulates the medicinal use of cannabis, let’s try to work together to make our contribution and be able to solve the drama of mothers head of household with children suffering the convulsions of epilepsy, let us be an example for the other countries of the world and let’s make a common front to avoid that the big multinationals turn us into a big cannabis maquiladora, and that we lose all its benefits, and that it happens to us what is happening in Chile, with an aggravating factor is that by producing our own raw material, we have to pay it at excessive prices, unattainable for low-income families.

 

Epilepsy in Colombia

Epilepsy in Colombia

With 450,000 people with epilepsy and a prevalence of 11 cases per 100,000 inhabitants, Colombia is one of the countries with more epilepsy in the world. In comparison with other developed countries that have better access to health and a prevalence of 4 cases per 100,000 inhabitants.

 

1.3% of the Colombian population suffers from epilepsy, a disease that represents 0.8% of the causes of mortality in the country. With regard to these statistics, the Congress of Colombia decreed in 2010 Law 1414, “which establishes special protection measures for people suffering from epilepsy, and dictates the principles and guidelines for their comprehensive care.”

 

This chronic disease that affects people of any age and is characterized by the tendency to suffer frequent seizures caused by abnormal electrical discharges of brain cells. In Colombia, 75% of these people are children under 15 years of age. The World Health Organization decided to include epilepsy among mental pathologies.

 

There is a growing demand for alternative solutions on the part of patients due to the lack of known cures and relief of symptoms. In addition, because one third of this population suffers what is known as refractory or refractory epilepsy, that is, it does not respond to conventional treatments. The majority of patients suffering from refractory epilepsy have unsuccessfully tried several attempts to control seizures with different medications (3 to 5 or more antiepileptic drugs and steroids), without success.

 

Medical cannabis for the treatment of epilepsy gained national attention in the United States when a girl named Charlotte obtained help and research from a Medicinal Cannabis group that revealed a reduction in the frequency of Charlotte seizures from 50 seizures per day to 2 -3 nocturnal seizures per month, these benefits have already been reported by many patients with epilepsy.

 

The Epilepsia Magazine, which is a publication of the League Against Epilepsy, dedicated its entire edition of June 2014 to the review of the uses of cannabis; or that the congress of the American Academy of Epilepsy, which lasts a week and is done once a year, devoted an entire day to lecturing on medicinal cannabis.

 

This notion is supported by empirical evidence published by the Official Journal of the International League against Epilepsy, which revealed that 48% of epileptologists and general neurologists, and 98% of patients with epilepsy would advise medicinal cannabis in severe cases of epilepsy.

 

Officially, the Colombian health system only treats epilepsy with orthodox or conventional treatments, which are not being successful. As of August 2016, the Colombian Congress approved a new law that regulates the medicinal use of cannabis and allows the commercial cultivation, processing and export of products derived from it.

 

According to the government, this is a step forward in changing the repressive drug laws of the country and orienting them to public health for the benefit of many patients and likewise calls for doctors and researchers to work on the issue. It is expected that treatment based on cannabis, expand to new medical alternatives once the law is fully implemented, with special emphasis on the treatment of epilepsy with medicinal cannabis.